Design of Next Generation Polymyxins with Lower Toxicity: The Discovery of SPR206

ACS Infectious Diseases

Volumn 5, Issue 10, 2019, Pages 1645-1656

  Brown, Pamela ^a,b   Abbott, Elizabeth ^a   Abdulle, Omar ^a   Boakes, Steven ^a   Coleman, Scott ^b   Divall, Naomi ^a   Duperchy, Esther ^a   Moss, Stephen ^c   Rivers, Dean ^a   Simonovic, Mona ^a   Singh, Jaspal ^a   Stanway, Steven ^c   Wilson, Antoinette ^c   Dawson, Michael J ^a,b  

^a BioPark Hertfordshire   (United Kingdom)

^b Drug Product Development   (United States)

^c Fyfield Business and Research Park ^*  (United Kingdom)

Author keywords

antibacterials; antimicrobial resistance; Gram negative; multidrug resistant bacteria; nephrotoxicity; polymyxin

Indexed keywords

POLYMYXIN; POLYMYXIN B; SPR 206; UNCLASSIFIED DRUG; AMINOBUTYRIC ACID DERIVATIVE; ANTIINFECTIVE AGENT;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DESIGN; HUMAN; HUMAN CELL; MALE; MOUSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; ANIMAL; BACTERIAL INFECTION; CELL LINE; DRUG EFFECT; KIDNEY; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE; PATHOLOGY; SYNTHESIS;

AMINOBUTYRATES; ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CELL LINE; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; KIDNEY; MALE; MICE; MICROBIAL SENSITIVITY TESTS; POLYMYXIN B; POLYMYXINS;

EID: 85073001909     PISSN: None     EISSN: 23738227     Source Type: Journal    
DOI: 10.1021/acsinfecdis.9b00217     Document Type: Article

References (38)

1. Cassini, A., Högberg, L. D., Plachouras, D., Quattrocchi, A., Hoxha, A., Simonsen, G. S., Colomb-Cotinat, M., Kretzschmar, M. E., Devleesschauwer, B., Cecchini, M., Ouakrim, D. A., Oliveira, T. C., Struelens, M. J., Suetens, C., Monnet, D. L. et al. (2019) Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect. Dis. 19, 56-66, 10.1016/S1473-3099(18)30605-4
2. Centers for Disease Control and Prevention (2013) Antibiotic Resistance Threats in the United States, 2013, Centers for Disease Control and Prevention, Atlanta, GA.
3. Burnham, J. P., Olsen, M. A., and Kollef, M. H. (2019) Re-estimating annual deaths due to multidrug-resistant organism infections. Infect. Control Hosp. Epidemiol. 40, 112-113, 10.1017/ice.2018.304
4. WHO (2017) Prioritization of pathogens to guide discovery, research and development of new antibiotics for drug-resistant bacterial infections including tuberculosis (WHO/EKP/IAU/2017.12), World Health Organization, Geneva.
5. Elias, L. S., Konzen, D., Krebs, J. M., and Zavascki, A. P. (2010) The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic. J. Antimicrob. Chemother. 65, 2231-2237, 10.1093/jac/dkq285
6. Justo, J. A. and Bosso, J. A. (2015) Adverse reactions associated with systemic polymyxin therapy. Pharmacotherapy 35 (1), 28-33, 10.1002/phar.1493
7. Mares, J., Kumaran, S., Gobbo, M., and Zerbe, O. (2009) Interactions of lipopolysaccharide and polymyxin studied by NMR spectroscopy. J. Biol. Chem. 284, 11498-11506, 10.1074/jbc.M806587200
8. Kanazawa, K., Sato, Y., Ohki, K., Okimura, K., Uchida, Y., Shindo, M., and Sakura, N. (2009) Contribution of each amino acid residue in polymyxin B to antimicrobial and lipopolysaccharide binding activity. Chem. Pharm. Bull. 57, 240-244, 10.1248/cpb.57.240
9. Abdelraouf, K., He, J., Ledesma, K. R., Hu, M., and Tam, V. H. (2012) Pharmacokinetics and Renal Disposition of Polymyxin B in an Animal Model. Antimicrob. Agents Chemother. 56 (11), 5724-5727, 10.1128/AAC.01333-12
10. Abdelraouf, K., Chang, K.-T., Yin, T., Hu, M., and Tam, V. H. (2014) Uptake of Polymyxin B into Renal Cells. Antimicrob. Agents Chemother. 58, 4200-4202, 10.1128/AAC.02557-14
11. Nilsson, A., Goodwin, R. J. A., Swales, J. G., Gallagher, R., Shankaran, H., Sathe, A., Pradeepan, S., Xue, A., Keirstead, N., Sasaki, J. C., Andren, P. E., and Gupta, A. (2015) Investigating Nephrotoxicity of Polymyxin Derivatives by Mapping Renal Distribution Using Mass Spectrometry Imaging. Chem. Res. Toxicol. 28, 1823-1830, 10.1021/acs.chemrestox.5b00262
12. Yun, B., Azad, M. A. K., Wang, J., Nation, R. L., Thompson, P. E., Roberts, K. D., Velkov, T., and Li, J. (2015) Imaging the distribution of polymyxins in the kidney. J. Antimicrob. Chemother. 70, 827-829, 10.1093/jac/dku441
13. Yun, B., Azad, M. A. K., Nowell, C. J., Nation, R. L., Thompson, P. E., Roberts, K. D., Velkov, T., and Li, J. (2015) Cellular Uptake and Localization of Polymyxins in Renal Tubular Cells Using Rationally Designed Fluorescent Probes. Antimicrob. Agents Chemother. 59, 7489-7496, 10.1128/AAC.01216-15
14. Velkov, T., Thompson, P. E., Nation, R. L., and Li, J. (2010) Structure-activity relationships of Polymyxin Antibiotics. (2010). J. Med. Chem. 53, 1898-1916, 10.1021/jm900999h
15. Vaara, M. (2013) Novel derivatives of polymyxins. J. Antimicrob. Chemother. 68, 1213-1219, 10.1093/jac/dkt039
16. Velkov, T., Roberts, K. D., Thompson, P. E., and Li, J. (2016) Polymyxins: a new hope in combating Gram-negative superbugs. Future Med. Chem. 8, 1017-1025, 10.4155/fmc-2016-0091
17. Brown, P. and Dawson, M. J. (2017) Development of new polymyxin derivatives for multi-drug resistant Gram-negative infections. J. Antibiot. 70, 386-394, 10.1038/ja.2016.146
18. Rabanal, F. and Cajal, Y. (2017) Recent advances and perspectives in the design and development of polymyxins. Nat. Prod. Rep. 34, 886-908, 10.1039/C7NP00023E
19. Vaara, M., Fox, J., Loidl, G., Siikanen, O., Apajalahti, J., Hansen, F., Frimodt-Møller, N., Nagai, J., Takano, M., and Vaara, T. (2008) Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents. Antimicrob. Agents Chemother. 52, 3229-3236, 10.1128/AAC.00405-08
20. Leese, R. A. (Biosource Pharm, Inc.) (July 1, 2010) Antibiotic compositions for the treatment of Gram Negative Infections, International Patent Application WO2010075416.
21. Magee, T. V., Brown, M. F., Starr, J. T., Ackley, D. C., Abramite, J. A., Aubrecht, J., Butler, A., Crandon, J. L., Dib-Hajj, F., Flanagan, M. E., Granskog, K., Hardink, J. R., Huband, M. D., Irvine, R., Kuhn, M., Leach, K. L., Li, B., Lin, J., Luke, D. R., MacVane, S. H., Miller, A. A., McCurdy, S., McKim, J. M., Jr., Nicolau, D. P., Nguyen, T. T., Noe, M. C., O'Donnell, J. P., Seibel, S. B., Shen, Y., Stepan, A. F., Tomaras, A. P., Wilga, P. C., Zhang, L., Xu, J., and Chen, J. M. (2013) Discovery of Dap-3 polymyxin analogues for the treatment of multidrug-resistant Gram-negative nosocomial infections. J. Med. Chem. 56, 5079-5093, 10.1021/jm400416u
22. Gallardo-Godoy, A., Muldoon, C., Becker, B., Elliott, A. G., Lash, L. H., Huang, J. X., Butler, M., Pelingon, R., Kavanagh, A. M., Ramu, S., Phetsang, W., Blaskovich, M. A. T., and Cooper, M. (2016) Activity and predicted nephrotoxicity of synthetic analogues based on Polymyxin B. J. Med. Chem. 59 (3), 1068-1077, 10.1021/acs.jmedchem.5b01593
23. Vaara, M., Vaara, T., and Tyrrell, J. M. (2017) Structure-activity studies on polymyxin derivatives carrying three positive charges only reveal a new class of compounds with strong antibacterial activity. Peptides 91, 8-12, 10.1016/j.peptides.2017.03.002
24. Vaara, M. (2019) Polymyxin Derivatives that Sensitize Gram-Negative Bacteria to Other Antibiotics. Molecules 24, 249-264, 10.3390/molecules24020249
25. Vaara, M., Siikanen, O., Apajalahti, J., Fox, J., Frimodt-Møller, N., He, H., Poudyal, A., Li, J., Nation, R. L., and Vaara, T. (2010) A novel Polymyxin derivative that lacks the fatty acyl tail and carries only three positive charges has strong synergism with agents excluded by the intact outer membrane. Antimicrob. Agents Chemother. 54, 3341-3346, 10.1128/AAC.01439-09
26. Eckburg, P., Farinola, N., Utley, L., Walpole, S., Keutzer, T., Kopp, E., Coleman, S., and Tomayko, J. (2018) Safety of SPR741, a novel polymyxin potentiator, in healthy adults receiving single-and multiple-dose intravenous administrations, Poster 2206, ECCMID, Madrid.
27. Li, B., Akin, A., Magee, T. V., Martinez, C., Szeliga, J., and Vuong, D. V. (2015) Syntheses of Dap-3 Polymyxin Analogues via a Tris-Boc-Protected Polymyxin B Heptapeptide. Synthesis 47, 2088-92, 10.1055/s-0034-1380549
28. Okimura, K., Ohki, K., Sato, Y., Ohnishi, K., Uchida, Y., and Sakura, N. (2007) Chemical conversion of natural polymyxin B and colistin to their N-terminal derivatives. Bull. Chem. Soc. Jpn. 80, 543-55, 10.1246/bcsj.80.543
29. Sakura, N., Itoh, T., Uchida, Y., Ohki, K., Okimura, K., Chiba, K., Sato, Y., and Sawanishi, H. (2004) The contribution of the N-terminal structure of polymyxin B peptides to antimicrobial and lipopolysaccharide binding activity. Bull. Chem. Soc. Jpn. 77, 1915-1924, 10.1246/bcsj.77.1915
30. Gallardo-Godoy, A., Hansford, K. A., Muldoon, C., Becker, B., Elliott, A. G., Huang, J. X., Pelingon, R., Butler, M. S., Blaskovich, M. A. T., and Cooper, M. A. (2019) Structure-Function Studies of Polymyxin B Lipononapeptides. Molecules 24, 553-566, 10.3390/molecules24030553
31. Katsuma, N., Sato, Y., Ohki, K., Okimura, K., Ohnishi, K., and Sakura, N. (2009) Development of des-fatty acyl-Polymyxin B decapeptide analogs with Pseudomonas aeruginosa-specific antimicrobial activity. Chem. Pharm. Bull. 57, 332-336, 10.1248/cpb.57.332
32. Apeland, I. M., Bjørnstad, V., Budnjo, A., Gunnes, S., Kenyon, R. F., and Larsson, C. A. R. (Xellia Pharmaceuticals APS) (Oct 20, 2016) Polymyxin Derivatives, International Patent Application WO2016166103.
33. Bowers, D. R., Cao, H., Zhou, J., Ledesma, K. R., Sun, D., Lomovskaya, O., and Tam, V. (2015) Assessment of minocycline and polymyxin B combination against Acinetobacter baumannii. Antimicrob. Agents Chemother. 59, 2720-2725, 10.1128/AAC.04110-14
34. He, J., Gao, S., Hu, M., Chow, D. S.-L., and Tam, V. H. (2013) A validated ultra-performance liquid chromatography-tandem mass spectrometry method for the quantification of polymyxin B in mouse serum and epithelial lining fluid: application to pharmacokinetic studies. J. Antimicrob. Chemother. 68, 1104-1110, 10.1093/jac/dks536
35. Lister, T., Utley, L., and Bleavins, M. (2018) A GLP 14 Day Repeat Dose Toxicology Study of SPR206 in Monkeys, Poster 146, ASM-ESCMID, Lisbon, Portugal.
36. Grosser, L., Heang, K., and Rubio, A. (2018) In Vivo Efficacy of SPR206 in an Immunocompetent Murine Ascending Urinary Tract Infection Model Caused by Escherichia coli, Poster 144, ASM-ESCMID, Lisbon, Portugal.
37. Grosser, L., Heang, K., Teague, J., Warn, P., Corbett, D., Dawson, M. J., and Rubio, A. (2018) In Vivo Efficacy of SPR206 in Murine Lung and Thigh Infection Models Caused by Multidrug Resistant Pathogens Pseudomonas aeruginosa and Acinetobacter baumanii, Poster 143, ASM-ESCMID, Lisbon, Portugal.
38. Clinical and Laboratory Standards Institute (2012) Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically: approved standard, 9 th ed., CLSI document M07-A9, CLSI, Wayne, PA.